Cortechs.ai and the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) have partnered to enhance Alzheimer’s disease care through AI-driven imaging solutions.
The partnership integrates Cortechs.ai’s NeuroQuant for ARIA platform with ALZ-NET’s real-world data network.
It aims to inform clinical decision-making and improve care delivery for Alzheimer’s patients.
Cortechs.ai’s NeuroQuant for ARIA provides precise segmentation, quantification, and tracking of FLAIR and T2GRE/SWI lesions.
The functionality aids in monitoring amyloid-related imaging abnormalities, like ARIA-E and ARIA-H, in patients undergoing anti-amyloid therapies.
The platform is validated on both 2D and 3D FLAIR sequences, ensuring broad compatibility with various imaging protocols.
Cortechs.ai Medical Advisory Board and ALZ-NET’s Imaging Work Group member Ana Franceschi said: “It is a privilege to serve on Cortechs.ai’s Medical Advisory Board as we embark on this important collaboration with ALZ-NET.
“Combining advanced neuroimaging analytics with real-world data is a critical step in optimizing safety and monitoring for Alzheimer’s patients receiving anti-amyloid therapies. This collaboration holds great promise for clinicians and patients alike.”
NeuroQuant for ARIA is the only clinically validated solution that detects and quantifies cerebral microbleeds and superficial siderosis on T2GRE and SWI scans.
It also offers FLAIR lesion quantification of cerebral edema, providing a comprehensive AI-assisted monitoring solution for Alzheimer’s patients on anti-amyloid immunotherapies.
ALZ-NET is a network of healthcare providers collecting real-world clinical and imaging data from patients evaluated for or treated with FDA-approved Alzheimer’s therapies.
The network is sponsored by the Alzheimer’s Association and managed by the American College of Radiology, and aims to provide insights into the long-term safety and efficacy.
Cortechs.ai CEO Kyle Frye said: “Alzheimer’s disease is a prevalent and devastating condition that touches millions of families.
“Our collaboration with ALZ-NET represents a shared commitment to using data and technology to improve how we care for people with dementia.
“With NeuroQuantfor ARIA, we’re giving clinicians the tools they need to make smarter, safer decisions, and by connecting with ALZ-NET’s powerful data network, we can collectively advance treatment practices for the entire field.”
